CD40 activation: potential for specific immunotherapy in B-CLL.

Abstract

Despite encouraging scientific and therapeutic advances, chronic lymphocytic leukemia (CLL) principally remains an incurable disease. Allogeneic transplantation represents the only curative approach, but is marked by high mortality. Novel and less toxic treatment modalities are needed. Immunotherapeutic approaches have clearly demonstrated potential effectiveness in CLL and other B-cell malignancies. To successfully direct immunity against CLL, highly immunogenic tumor cells or tumor-antigen-loaded antigen-presenting cells are necessary. The CD40-CD40L interaction has been shown to significantly increase antigen presentation in normal and malignant B-cells. Here we discuss biology and potential therapeutic applications of the CD40-system in CLL.

Statistics

050100'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

273 Citations

Semantic Scholar estimates that this publication has 273 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{BergweltBaildon2004CD40AP, title={CD40 activation: potential for specific immunotherapy in B-CLL.}, author={Michael S. von Bergwelt-Baildon and Britta Maecker and J L Schultze and John G Gribben}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2004}, volume={15 6}, pages={853-7} }